Mark Joseph Cantwell
Director Técnico/Científico/I+D en Memgen, Inc. .
Perfil
Mark Joseph Cantwell is currently the Chief Scientific Officer & Director at Memgen, Inc. Previously, he worked as the Vice President-Research & Development at Mast Therapeutics, Inc. He completed his undergraduate degree at Georgia Institute of Technology and his doctorate at the University of California San Diego.
Cargos activos de Mark Joseph Cantwell
| Empresas | Cargo | Inicio |
|---|---|---|
Memgen, Inc.
 Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Mark Joseph Cantwell.
| Empresas | Cargo | Fin |
|---|---|---|
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | - |
Formación de Mark Joseph Cantwell.
| Georgia Institute of Technology | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Memgen, Inc.
Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Mark Joseph Cantwell
